Revive Therapeutics Shares Data from Cannabinoid-Based Therapies Research

Cannabis Investing News
Cannabis Investing

Revive Therapeutics shared positive results from their research program of cannabinoid-based therapies targeting liver diseases.

Revive Therapeutics (TSXV:RVV; OTCQB:RVVTF) shared positive results from their research program of cannabinoid-based therapies targeting liver diseases.
As quoted in the press release:

“I am very pleased to have led and managed a unique drug discovery program involving phytocannabinoids, which has resulted in the discovery of novel compounds for the potential treatment of liver fibrosis and other liver disease indications that will be further explored,” said Dr. Pritesh Kumar, Scientific Advisor for the Company and Chief Executive Officer of PhytoSciences Consulting LLC. “The research that was sponsored by Revive completes a critical step in advancing novel compounds as potential therapeutics for specific liver diseases. I look forward to be the first to report these findings from the research program that I led and I am excited to contribute my expertise to further validate and potentially advance these discoveries for liver diseases.”
“We are very pleased with the outcome of our research program for the discovery and the validation of a number of cannabinoids for the treatment of liver fibrosis,” said Craig Leon, Chief Executive of Revive. “We remain focused on building a liver disease franchise, via research and development, licensing, and strategic partnering, that will be unique to the pharmaceutical community and targeting significantly unmet medical needs in a number of liver disease indications.”

Click here to read the full press release.

Source: www.marketwired.com

RVV:CC
The Conversation (0)
×